Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Coherus Oncology, Inc. (CHRS : NSDQ)

• Company Description    Coherus is a fully integrated commercial-stage innovative oncology company. Coherus, formerly known as Coherus BioSciences Inc., is based in REDWOOD CITY, Calif. Number of Employees: 306

• Price / Volume Information    Yesterday's Closing Price: $0.74 Daily Weekly Monthly 20 Day Moving Average: 1,260,389 shares Shares Outstanding: 115.93 (millions) Market Capitalization: $86.15 (millions) Beta: 0.88 52 Week High: $2.43 52 Week Low: $0.66 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.61% -8.65% 12 Week -4.95% -21.87% Year To Date -46.15% -48.69%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 333 TWIN DOLPHIN DRIVE SUITE 600 - REDWOOD CITY,CA 94065 USA ph: 650-649-3530 fax: - ir@coherus.com http://www.coherus.com

• General Corporate Information    Officers Dennis M. Lanfear - Chief Executive Officer; Chairman and President Bryan McMichael - Chief Financial Officer Georgia Erbez - Director Lee N. Newcomer - Director Charles Newton - Director Peer Information Coherus Oncology, Inc. (CORR.) Coherus Oncology, Inc. (RSPI) Coherus Oncology, Inc. (CGXP) Coherus Oncology, Inc. (BGEN) Coherus Oncology, Inc. (GTBP) Coherus Oncology, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 19249H103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 115.93 Most Recent Split Date: (:1) Beta: 0.88 Market Capitalization: $86.15 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.25 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.45 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: 2.55 Price / Sales: 0.44 EPS Growth vs. Year Ago Period: -7.89% vs. Previous Quarter: 6.82% Sales Growth vs. Year Ago Period: -90.14% vs. Previous Quarter: -85.97% ROE 03/31/25 - - 12/31/24 - - 09/30/24 - - ROA 03/31/25 - -26.51 12/31/24 - -21.44 09/30/24 - -24.44 Current Ratio 03/31/25 - 1.22 12/31/24 - 1.21 09/30/24 - 1.25 Quick Ratio 03/31/25 - 1.20 12/31/24 - 0.96 09/30/24 - 1.09 Operating Margin 03/31/25 - -67.10 12/31/24 - -48.02 09/30/24 - -51.65 Net Margin 03/31/25 - -66.30 12/31/24 - 10.68 09/30/24 - -0.15 Pre-Tax Margin 03/31/25 - 24.88 12/31/24 - 10.68 09/30/24 - -56.31 Book Value 03/31/25 - -1.58 12/31/24 - -1.14 09/30/24 - -0.76 Inventory Turnover 03/31/25 - 2.59 12/31/24 - 1.94 09/30/24 - 2.31 Debt-to-Equity 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Capital 03/31/25 - - 12/31/24 - - 09/30/24 - -

Powered by Zacks Investment Research ©